Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Leap Therapeutics, Inc.
LPTX
$0.6264
Name : Leap Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $25,957,720.00
EPSttm : -1.58
finviz dynamic chart for LPTX
Leap Therapeutics, Inc.
$0.6264
17.98%
$0.1373

Float Short %

4.25

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

0.2

EPS Last/This Y

0.7

EPS This/Next Y

0.58

Price

0.63

Target Price

5.5

Analyst Recom

3

Performance Q

83.86

Relative Volume

2

Beta

-0.09

Ticker: LPTX




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08LPTX0.28190.070.005861
2025-09-09LPTX0.28270.070.005860
2025-09-10LPTX0.28020.070.005859
2025-09-11LPTX0.28770.070.005867
2025-09-12LPTX0.29430.070.005868
2025-09-15LPTX0.30490.070.015879
2025-09-16LPTX0.31390.070.005982
2025-09-17LPTX0.31290.07089419308870706012
2025-09-18LPTX0.32160.070.006051
2025-09-19LPTX0.28980.070.196161
2025-09-22LPTX0.30480.090.004401
2025-09-23LPTX0.290.060.006092
2025-09-24LPTX0.30180.060.006351
2025-09-25LPTX0.34050.050.007632
2025-09-26LPTX0.33840.050.007397
2025-09-29LPTX0.35640.050.007421
2025-09-30LPTX0.45230.050.007453
2025-10-01LPTX0.52440.050.007672
2025-10-02LPTX0.73390.050.237817
2025-10-03LPTX0.50520.050.027911
2025-10-06LPTX0.74860.050.178198
2025-10-07LPTX0.61820.110.0312392
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08LPTX0.2945.5- -1.11
2025-09-09LPTX0.2845.5- -1.11
2025-09-10LPTX0.2845.5- -1.11
2025-09-11LPTX0.2945.5- -1.11
2025-09-12LPTX0.3045.5- -1.11
2025-09-15LPTX0.3145.5- -1.11
2025-09-16LPTX0.3245.5- -1.11
2025-09-17LPTX0.3145.5- -1.11
2025-09-18LPTX0.3245.5- -1.11
2025-09-19LPTX0.2945.5- -1.11
2025-09-22LPTX0.3145.5- -1.11
2025-09-23LPTX0.2945.5- -1.11
2025-09-24LPTX0.3045.5- -1.11
2025-09-25LPTX0.3545.5- -1.11
2025-09-26LPTX0.3545.5- -1.11
2025-09-29LPTX0.3645.5- -1.11
2025-09-30LPTX0.4545.5- -1.11
2025-10-01LPTX0.5245.5- -1.11
2025-10-02LPTX0.7445.5- -1.11
2025-10-03LPTX0.5345.5- -1.11
2025-10-06LPTX0.7545.5- -1.11
2025-10-07LPTX0.6345.5- -1.11
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08LPTX0.00-24.215.19
2025-09-09LPTX0.00-24.215.19
2025-09-10LPTX0.00-24.215.19
2025-09-11LPTX0.00-24.214.92
2025-09-12LPTX0.00-24.214.92
2025-09-15LPTX0.00-24.214.92
2025-09-16LPTX0.00-24.214.92
2025-09-17LPTX0.00-24.214.92
2025-09-18LPTX0.00-24.214.92
2025-09-19LPTX0.00-24.214.92
2025-09-22LPTX0.00-24.214.92
2025-09-23LPTX0.00-24.214.92
2025-09-24LPTX0.00-24.214.92
2025-09-25LPTX0.00-24.214.25
2025-09-26LPTX0.00-24.214.25
2025-09-29LPTX0.00-24.214.25
2025-09-30LPTX0.00-24.214.25
2025-10-01LPTX0.00-24.214.25
2025-10-02LPTX0.00-24.214.25
2025-10-03LPTX0.00-24.214.25
2025-10-06LPTX0.00-6.784.25
2025-10-07LPTX0.00-6.784.25
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

-6.78

Beta

-0.09

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

4

Growth Score

19

Sentiment Score

56

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-99.4

Target Price

5.5

P/E

Forward P/E

PEG

P/S

P/B

4.54

P/Free Cash Flow

EPS

-1.59

Average EPS Est. Cur. Y​

-1.11

EPS Next Y. (Est.)

-0.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2

Return on Equity vs Sector %

-1174.1

Return on Equity vs Industry %

-1160.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

Leap Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 52
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
stock quote shares LPTX – Leap Therapeutics Inc Stock Price stock today
news today LPTX – Leap Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPTX – Leap Therapeutics Inc yahoo finance google finance
stock history LPTX – Leap Therapeutics Inc invest stock market
stock prices LPTX premarket after hours
ticker LPTX fair value insiders trading